Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
1. Genotype 4 hepatitis C virus-a review of a diverse genotype
- Brzdęk M. , et al.
2. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center
- El Kassas M. , et al.
3. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience
- Naguib G.G. , et al.
4. ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides
- Timmons P.B. , et al.
5. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting
- Naguib G.G. , et al.
6. Serum MicroRNAs as predictors for fibrosis progression and response to direct-acting antivirals treatment in hepatitis C virus genotype-4 Egyptian patients
- Khairy R.M.M. , et al.
7. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt
- Esmat G. , et al.
8. Antiviral peptides as promising therapeutic drugs
- Vilas Boas L.C.P. , et al.
9. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations
- Omran D. , et al.
10. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir
- Schnell G. , et al.
11. HCV in Egypt, prevention, treatment and key barriers to elimination
- El Kassas M. , et al.
12. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens
- El-Raziky M. , et al.
14. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt
- Nagaty A. , et al.
15. Association of vitamin D binding protein polymorphisms with response to therapy in Egyptian chronic hepatitis C patients
- Kamel A.M. , et al.
17. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care
- El-Akel W. , et al.
18. Management of hepatitis C genotype 4 in the directly acting antivirals era
- Hathorn E. , et al.
19. Correlation between vitamin D levels and apoptosis in geriatric patients infected with hepatitis C virus genotype 4
- Gabr S.A. , et al.
20. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy
- Esmat G.E. , et al.
21. The effect of the degree of hepatitis C-related fibrosis on the responsiveness to pegylated interferon α-2a versus pegylated interferon α-2b: Egyptian study
- El Shazly Y.M. , et al.
22. Bcl-2 and p53 expression in hepatic tissues of Egyptian patients with Chronic Hepatitis C
- Allam A. , et al.
23. Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C
- Pouresmaeeli M. , et al.
24. A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients
- El Sabaawy D. , et al.
25. Hepatitis C genotype 4: The past, present, and future
- Abdel-Ghaffar T.Y. , et al.